drugset / Trial / NCT06559007

Phase 1 Study to Evaluate PK, Safety, and Tolerability of HRS-5041 in Healthy Caucasian Male Participants

NCT06559007

Phase 1 Completed 24 enrolled Atridia Pty Ltd.
RandomizedSequentialOpen-labelTreatment

Summary

This is a phase 1, open-label, randomized study. The objective of this study is to evaluate the PK, safety and tolerability of orally administered single-dose HRS-5041 in healthy Caucasian male participants.

Timeline

Start
2024-09-25
Primary completion
2025-01-06
Completion
2025-03-03

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS-5041 Other / unclassified Oral

Indications